Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14022676 | 0.86 | HSPA5 (0.57) | HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL12309162 | 0.80 | HSPA5 (0.60) | HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL27620852 | 0.80 | GAA (0.49) | CYP2C9CYP2C19HIF1ASMN1; SMN2CYP2D6 | |
| SCHEMBL2230912 | 0.78 | HSPA5 (0.78) | HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL29558774 | 0.78 | HSPA5 (0.78) | HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL28320829 | 0.76 | HSPA5 (0.63) | HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL2162942 | 0.75 | HSPA5 (0.72) | HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL30061702 | 0.75 | HSPA5 (0.72) | HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2 | |
| Phenol SCHEMBL23706530 | 0.75 | HSPA5 (0.77) | HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL4459522 | 0.75 | HSPA5 (0.72) | HSPA5CYP2C9CYP2C19HIF1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260358-B2 | Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains a phenoxy ligand that is functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2016-02-16 | — | — | US | disclosed |
| US-9260358-B2 | Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains a phenoxy ligand that is functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2016-02-16 | — | — | US | disclosed |
| US-20110213190-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS A PHENOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP (FR) | 2011-09-01 | — | — | US | disclosed |
| US-20110213190-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS A PHENOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP (FR) | 2011-09-01 | — | — | US | disclosed |
| WO-2008142295-A1 | METHOD FOR OLIGOMERISING OLEFINS USING A CATALYTIC COMPOSITION COMPRISING AN ORGANOMETAL COMPLEX CONTAINING A PHENOXY LIGAND FUNCTIONALISED BY A HETEROATOM | IFP (FR) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213190-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS A PHENOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | HAO2, CPNE4, POF1B | HSPA5 2892/4885CYP2C9 1199/4885CYP2C19 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.